Taranto-Montemurro L, Messineo L, Azarbarzin A, et al. - In recent work of researchers, a great reduction in obstructive sleep apnea (OSA) severity, via increasing upper airway dilator muscle activity during sleep, was noted after administration of the combination of the noradrenergic drug atomoxetine plus the antimuscarinic oxybutynin (ato-oxy) prior to sleep, so, experts assessed how the drug combination (n = 17) and the single drugs (n = 6) vs placebo influenced the endotypic traits over a 1-night administration among patients with OSA who performed the ato-oxy trial with an esophageal pressure catheter to estimate ventilatory drive. Whether the complete response to therapy [reduction in AHI (apnea hypopnea index) > 50% and < 10 events/h] could be predicted by specific traits, was also investigated. The inquiry was a double-blinded randomized, placebo-controlled trial. A marked improvement in the measures of upper airway collapsibility, an increase in breathing stability and a slight decrease in the arousal threshold were brought about by Ato-oxy. The likelihood of resolving OSA with ato-oxy is suggested to be the greatest among patients with relatively lower AHI and less severe upper airway collapsibility.